Prenumeration
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
STENOCARE A/S (“STENOCARE” or the “Company”) is a medical cannabis trading company with products approved and available for patients in six countries. The Company has launched a premium product, Astrum 10-10, which Analyst Group sees as an important growth driver in the coming years, as it distinguishes STENOCARE from competitors. The product became available to patients in three countries, which in combination with a strategic acquisition of CannGros is expected to drive strong sales growth. With estimated net sales of DKK 22.5m by 2027, an applied P/S multiple of 3.8x and a discount rate of 13%, a potential present value per share of DKK 1.58 (1.01) is derived in a Base scenario.
Read the equity research report here
About Analyst Group: One of Sweden's leading analysis houses with a focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of an equity research report on STENOCARE. Readers may assume that Analyst Group has received compensation for making the equity research report. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation, or anything else that could be considered a subjective assessment.